menu
    • menu
    [{"orgOrder":0,"company":"Amal Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ATP128","moa":"Immune","graph1":"Oncology","graph2":"Phase I","graph3":"Amal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amal Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Amal Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amal Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VSV-GP154","moa":"Immune","graph1":"Oncology","graph2":"Phase I","graph3":"Amal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amal Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Amal Therapeutics \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Amal Therapeutics

    Menu

    Amal Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amal Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Amal Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VSV-GP154

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KIS...

                            Details : VSV-GP154 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Pancreatic Ductal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : VSV-GP154

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amal Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Amal Therapeutics

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATP128

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

                            Details : ATP128 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 06, 2019

                            Lead Product(s) : ATP128

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth